Trial of SBRT With Concurrent Ipilimumab in Metastatic Melanoma

Inclusion Criteria: * Signed informed consent and willingness to comply to the treatment and follow-up * Histological diagnosis of melanoma, * at least 3 extracranial measurable metastatic lesions per RECIST 1.1, * Karnofsky Performance score \>60, * Age ≥18, * Life expectancy ≥ 16 weeks * Women of childbearing potential must have a negative serum pregnancy test within 14 days of first dose of study treatment. Men and women should agree to use effective contraception, during the study and for 1 month following the last dose of investigational product. * ≥ 28 days between last treatment with standard or experimental chemotherapy, surgery, radiotherapy, cytokine therapy or immunotherapy. Patient should be completely recuperated of any clinical toxicity developed during previous treatments. * Patients should have adequate organ function for ipilimumab treatment Exclusion Criteria: * Central nervous system (CNS) metastases at baseline, with the exception of those subjects who have previously-treated CNS metastases (surgery ± radiotherapy, radiosurgery, or gamma knife) and who meet both of the following criteria: a) are asymptomatic and b) have no requirement for steroids or enzyme-inducing anticonvulsants. * Prior malignancy: Subjects who have had another malignancy and have been disease-free for 5 years, or subjects with a history of completely resected non-melanomatous skin carcinoma or successfully treated in situ carcinoma are eligible * Prior radiotherapy preventing treatment with SBRT. * Disorder precluding understanding of trial information. * Autoimmune disease: Patients with a history of inflammatory bowel disease (including Crohn's disease and ulcerative colitis) and autoimmune disorders such as rheumatoid arthritis, systemic progressive sclerosis \[scleroderma\], Systemic Lupus Erythematosus or autoimmune vasculitis \[e.g., Wegener's Granulomatosis\] are excluded from this study. * Known Human Immunodeficiency Virus (HIV), Hepatitis B, or Hepatitis C. * Concomitant therapy with any of the following: IL-2, interferon or other non-study immunotherapy regimens; cytotoxic chemotherapy; immunosuppressive agents; other investigational therapies; or chronic use of systemic corticosteroids (used in the management of cancer or non-cancer-related illnesses). * Pregnant women * Breast feeding * History of or current immunodeficiency disease or prior treatment compromising immune function, prior allogeneic stem cell transplantation.